Cilostazol Dosing for Peripheral Arterial Disease
The recommended dose of cilostazol for patients with peripheral arterial disease and intermittent claudication is 100 mg orally twice daily, taken 30 minutes before or 2 hours after breakfast and dinner. 1, 2
Standard Dosing Regimen
- Dose: 100 mg twice daily (BID) 1
- Timing: Administer 30 minutes before or 2 hours after meals (specifically breakfast and dinner) 3
- Duration: Continue for at least 12-24 weeks to assess therapeutic benefit 1
The 100 mg BID dose is significantly more effective than the 50 mg BID dose, improving maximal walking distance by 40-60% after 12-24 weeks of therapy. 1
Dose Adjustment Strategy
Initial tolerability approach: Some clinicians start with a reduced dose (50 mg BID) to minimize early side effects, particularly headache, with planned escalation to 100 mg BID within 4 weeks. 4 However, this is not the guideline-recommended approach and may compromise efficacy. 1
With CYP inhibitors: Consider dose reduction when cilostazol is coadministered with:
Clinical Indications
Class I recommendation (strongest): Cilostazol is indicated for all patients with lifestyle-limiting intermittent claudication in the absence of heart failure. 1
Expected outcomes:
- 40-60% improvement in maximal walking distance 1
- 47-96 meter increase in absolute claudication distance 6
- Improvements typically evident by 2-4 weeks, with continued benefit through 24 weeks 7, 6
Absolute Contraindication
Heart failure of any severity: Cilostazol must not be administered to patients with congestive heart failure due to its mechanism as a phosphodiesterase III inhibitor, which has been associated with increased mortality in heart failure patients with other agents in this class. 1 This carries an FDA black-box warning. 1
Assessment of Treatment Response
- Early tolerance check: Evaluate patient tolerance at 2-4 weeks 1
- Efficacy assessment: Determine therapeutic benefit within 3-6 months to decide on continuation 1
- Discontinuation rate: Approximately 20% of patients discontinue within 3 months, primarily due to adverse effects 1
Common Adverse Effects
The most frequent side effects include:
- Headache (most common—occurs 2.8 times more often than placebo) 1
- Diarrhea and abnormal stools 1, 6
- Dizziness 1, 6
- Palpitations 1, 6
These adverse effects are generally mild to moderate, self-limited, and rarely require treatment withdrawal. 5
Additional Clinical Considerations
Emerging indication: Cilostazol may be useful to reduce restenosis after endovascular therapy for femoropopliteal disease, though this carries a Class IIb (may be considered) recommendation. 1
Cardiovascular safety: Multiple trials have not demonstrated increased cardiovascular mortality with cilostazol (0.6% vs 0.5% with placebo at 6 months). 1